Back

Prognostic Impact and Structural Recovery in HFrEF Patients on Vericiguat with PH and Tricuspid Regurgitation: Results from the VERISEC Registry

30 August 2026 (12:40 - 12:50)
Organised by: Logo
Congress Presentation Part of: From shock to recovery: rethinking risk, rhythm, and remodelling Ventricular Remodelling ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Esteban Fernandez

Severo Ochoa Hospital, Leganes (Spain)

5 More presentations in this session

Presentation thumbnail
Hybrid cardiac rehabilitation at anaerobic threshold reduces myocardial fibrosis and improves outcomes in HFrEF post-MI: a multicenter RCT
Doctor R. Ding (Beijing, CN)
Abstract Slides
Presentation thumbnail
GDF-15 as an early marker for prognosis in patients with cardiogenic shock
Professor A. Schaefer (Hannover, DE)
Abstract Slides
Presentation thumbnail
Machine learning–based proteomic phenogrouping identifies an inflammatory high-risk subtype in HFpEF : results from the PACIFIC-PRESERVED study
Professor J. Hulot (Paris, FR)
Abstract Slides
Presentation thumbnail
Efficacy and safety of percutaneous stellate ganglion block technique in patients with electrical storm complicated by cardiogenic shock
Doctor A. Morena (Pavia, IT)
Abstract Slides
Presentation thumbnail
Sex differences in infarct–related cardiogenic shock: a secondary analysis of the ECLS–SHOCK trial
Doctor M. Buske (Leipzig, DE)
Abstract Slides

Access the full session

Session thumbnail
From shock to recovery: rethinking risk, rhythm, and remodelling
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 12:40 CET
You may be interested in
thumbnail
Congress Presentation
TAPSE/RVSP ratio as an echocardiographic marker of residual risk in HFrEF patients receiving vericiguat
11 December 2025
thumbnail
Congress Presentation
The tricuspid valve in heart failure progression
22 May 2023
thumbnail
Congress Presentation
Short-term impact of percutaneous tricuspid valve repair on right ventricular remodeling
12 December 2025
thumbnail
Congress Presentation
Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources